Design and Validation of new TLR agonists for therapeutic vaccination in oncology: MIP: Amal Therapeutics

• Research unit: INNOSUISSE
• Project number: 17388.2 PFLS-LS

Short description (German)

Design and Validation of new TLR agonists for therapeutic vaccination in oncology

Short description (English)

Design and Validation of new TLR agonists for therapeutic vaccination in oncology: MIP: Amal Therapeutics

Abstract (German)

Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .

Abstract (English)

Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .